Hope does remain that therapies are being developed that might tackle this disease and it is noteworthy, and illustrates the eagerness of regulatory authorities to bring medicines forward, that the FDA recently gave Roches Actemra (tocilizumab), an anti-IL-6 receptor antibody, breakthrough status for systemic sclerosis 1 even though the primary endpoints weren't met, but showed a positive trend in Rodnin skin score, in their recent Phase II study (Khanna et al., 2014 ).
1
—
—